In the last decade, immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have proved to be a promising treatment option for patients with advanced/metastatic NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.